James Nezamis

Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States.

Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States.

Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States.

Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States.

Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States.